Tuberculosis Vaccine

Boosting with M. tuberculosis major secretory protein enhances BCG vaccine protection

Published in Vaccine Weekly, December 14th, 2005

Boosting with the Mycobacterium tuberculosis major secretory protein enhances the protective efficacy of M. bovis BCG vaccination against tuberculosis.

According to a study from the United States, "Tuberculosis continues to ravage humanity, killing two million people yearly. Most cases occur in areas of the world to which the disease is endemic, where almost everyone is vaccinated early in life with M. bovis BCG, the currently available vaccine against tuberculosis. Thus, while more potent vaccines are needed to replace BCG, new vaccines are also needed to boost the immune protection of the four billion people already vaccinated with BCG."

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2005-12-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry